abraxane,irinotecan,paclitaxel,bevacizumab
roche,amgen,ipsen
['strategic-1', 'irinotecan', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'sequence,(-consequence)']
dr. chibaudel w/ strategic-1: gercor-prodige p3 study of ras/braf mcrc: folfiri-cetux folfox-bev vs optimox-bev folfiri-bev anti-egfr +/- irinotecan. primary endpoint was duration of dz control (sum of pfs of each active sequence of tx) and was similar (hr 0.97). #asco22 
Gastrointestinal medical oncology, cancer of unknown primary, and value-based cancer care delivery. Tweets mine.